Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

NCT03036904 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma

Interventions

DRUG: Venetoclax
DRUG: Rituximab
DRUG: Etoposide
DRUG: Vincristine Sulfate
DRUG: Cyclophosphamide
DRUG: Prednisone
DRUG: Doxorubicin Hydrochloride

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]
[object Object]
[object Object]